Bristol Myers Squibb A+ rated Bristol Myers Squibb (BMY) is a blue-chip dividend growth stock offering a 3% and growing current yield. Historically, this stalwart pharmaceutical giant has commanded a premium valuation multiple by Mr. Market. However, since November 2018 Bristol Myers has been selling at a discount to not only its historical norms but …
Bristol Myers
Subscriber Request Series: Celgene Corp (NAS:CELG) and Bristol Myers (NYS:BMY)
FAST Graphs Analyze Out Loud Celgene Corp $CELG: Celgene Corp. is an integrated global biopharmaceutical company, which engages in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases. Its primary commercial stage products include REVLIMID, POMALYST, IMNOVID, OTEZLA, ABRAXANE, and VIDAZA. The company was founded by David Stirling and …